Section Arrow
Quote
ODTX.NASDAQ
- Odyssey Therapeutics, Inc.
Quotes are at least 15-min delayed:2026/11/11 16:50 EST
After Hours
Last
 20.99
0 (0.00%)
Bid
17.99
Ask
21.99
High 21.4 
Low 20.7 
Volume 5.84K 
Regular Hours (Closed)
Last
 20.99
+0.99 (+4.95%)
Day High 
21.21 
Prev. Close
20 
1-M High
22.36 
Volume 
245.07K 
Bid
17.99
Ask
21.99
Day Low
19.22 
Open
19.98 
1-M Low
16.36 
Market Cap 
961.36M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 19.68 
20-SMA 19.08 
50-SMA 20.98 
52-W High 29.05 
52-W Low 15.1 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.70/-5.13
Enterprise Value
983.26M
Balance Sheet
Book Value Per Share
7.82
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
4.47M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.59+0.04+1.13%-- 
After Hours 3.5996 +0.0096 +0.27%
PEPGPepGen5.26+0.65+14.10%-- 
After Hours 5.3 +0.04 +0.76%
ALLOAllogene Therapeutics0.9001-0.0318-3.41%-- 
After Hours 0.9181 +0.018 +2.00%
ERASErasca16.8+1.32+8.53%-- 
After Hours 16.8 0 0.00%
PRMEPrime Medicine4.3+0.4+10.26%-- 
After Hours 4.22 -0.08 -1.86%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.